

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization

International Bureau

(43) International Publication Date  
05 October 2023 (05.10.2023)



(10) International Publication Number  
**WO 2023/192960 A1**

(51) International Patent Classification:

C07F 9/40 (2006.01) A61P 29/00 (2006.01)  
C07D 471/04 (2006.01) A61P 35/00 (2006.01)  
C07D 487/04 (2006.01)

(21) International Application Number:

PCT/US2023/065171

(22) International Filing Date:

30 March 2023 (30.03.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/325,908 31 March 2022 (31.03.2022) US  
63/337,388 02 May 2022 (02.05.2022) US

(71) Applicant: RECLUDIX PHARMA, INC. [US/US]: 222  
Third Street, Suite 1320, Cambridge, MA 02142 (US).

(72) Inventors: BIFULCO, Neil; 15 Lillian Ave, Sudbury, MA 01776 (US). BREGMAN, Howard; 12 Howard St., Melrose, MA 02176 (US). CIANCHETTA, Giovanni; 82 Herrick Rd, Boxford, MA 01921 (US). HODOUS, Brian; 22 Lawrence Lane, Arlington, MA 02474 (US). REZNIK, Samuel, K.; 35 Walden St, Apt. 3F, Cambridge, MA 02140 (US). TANG, Yong; 6 Plover St, West Roxbury, MA 02132 (US). TASKER, Andrew; 277 Talbert Ave, Simi Valley, CA 93065 (US). VASWANI, Rishi, G.; 219 Lowell Street, Lexington, MA 02421 (US). SICKMIER, Ernest, Allen; 61 Hunting Rd, Needham, MA 02494 (US). YEOMAN, John; 215 Harvard St Unit 13, Medford, MA 02155 (US). TIAN, Xia; 931 Massachusetts Ave. #604, Cambridge, MA 02139 (US).

(74) Agent: DEGRAZIA, Michael J. et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: STAT MODULATORS AND USES THEREOF

(57) Abstract: Provided are compounds of Formula (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with STAT3 and/or STAT6.



(I)

WO 2023/192960 A1